Share This Author
Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells.
The results suggest that relevant biological effects of porphyrins can be achieved at concentrations that do not have general cytotoxic effects on cells, and support the concept that a rational, structure-based approach is possible to design novel telomere-interactive agents with application to a selective and specific anticancer therapy.
The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures.
- Mu-yong Kim, M. Gleason-Guzman, E. Izbicka, D. Nishioka, L. Hurley
- Chemistry, BiologyCancer research
- 15 June 2003
This study has demonstrated that telomestatin interacts preferentially with intramolecular versus intermolecular G-quadruplex structures and also has a 70-fold selectivity for intramolescular G -quadru Plex structures over duplex DNA, and induces anaphase bridges in sea urchin embryos, whereas TMPyP4 did not have this effect.
Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
The first stage of a National Cancer Institute/Early Detection Research Network-sponsored multiinstitutional evaluation and validation of SELDI-TOF-MS serum profiling approaches that of "within-laboratory" reproducibility as determined by measuring discrete m/z peaks over time and across laboratories.
Activity of oxaliplatin against human tumor colony-forming units.
- E. Raymond, R. Lawrence, E. Izbicka, S. Faivre, D. V. Von Hoff
- Biology, ChemistryClinical cancer research : an official journal of…
- 1 April 1998
The data indicate that oxaliplatin is an active drug in vitro against a large variety of human tumors and the broad spectrum of activity and the in vitro activity against some tumors primarily resistant to conventional anticancer drugs encourage further clinical investigations of oxali Platin in patients with advanced cancer refractory to conventional chemotherapy.
A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with…
The absence of severe toxicities at this recommended dose, evidence of Bcl-2 protein inhibition in peripheral blood mononuclear cell(s) and tumor tissue, and encouraging antitumor activity in HPRC patients warrant further clinical evaluation of this combination.
A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer
The absence of severe toxicities at this recommended dose, evidence of Bcl-2 protein inhibition, and encouraging antitumor activity in HPRC patients warrant further clinical evaluation of this combination.
Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide
- W. Rodrigueza, Michael J. Woolliscroft, A. Al-Katib
- Biology, ChemistryCancer Chemotherapy and Pharmacology
- 16 May 2014
PNT2258 is PNT100 that is encapsulated in protective amphoteric liposomes developed to efficiently encapsulate the PNT 100 oligonucleotide, provide enhanced serum stability, optimized pharmacokinetic properties and antitumor activity of the nanoparticle both in vivo and in vitro.
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
- E. Izbicka, R. Lawrence, D. V. Von Hoff
- Biology, MedicineAnnals of oncology : official journal of the…
- 1 September 1998
The data from the cloning assay indicate that the duration of exposure to ET-743 is an important factor in human tumors, and long-term exposure to the novel compound may be preferred in future clinical trials.
Activity of temozolomide against human tumor colony-forming units.
- E. Raymond, E. Izbicka, H. Soda, S. Gerson, M. Dugan, D. V. Von Hoff
- Medicine, BiologyClinical cancer research : an official journal of…
- 1 October 1997
Data indicate both that temozolomide is an active drug in vitro against a large variety of human tumors, including some tumors usually resistant to conventional chemotherapy, and that further clinical evaluation is warranted.
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
- M. Mita, L. Ochoa, A. Tolcher
- Medicine, BiologyAnnals of oncology : official journal of the…
- 1 February 2006
The combination is well tolerated at the recommended phase II oblimersen sodium dose of 7 mg/kg/day CIVI days 1-8 with irinotecan 280 mg/m2 intravenously on day 6 every 3 weeks.